trending Market Intelligence /marketintelligence/en/news-insights/trending/uiSvJ26_t4Us_G4gjPcFow2 content esgSubNav
In This List

Catalent to invest $200M in biologics manufacturing expansion

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Catalent to invest $200M in biologics manufacturing expansion

Catalent Inc. started a $200 million capital investment program to expand its biologics manufacturing capacity and capabilities.

Under the three-year investment program, Catalent will increase the mammalian cell culture capacity of its Madison, Wis.-based facility by building two new suites. The company expects to complete the construction by mid-2021, resulting in a more than doubled commercial biomanufacturing capacity.

The company will also extend its Bloomington, Ind.-based site by 79,000 square feet to boost the facility's fill and finish capacity. In December 2018, Catalent invested $14 million to expand the biologics packaging capabilities of the Bloomington facility.

Somerset, N.J.-based Catalent provides advanced delivery technologies and development for drugs, biologics and consumer health products.